JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Kodu・Aktsiate loetelu・Ovid therapeutics Inc

Ovid therapeutics Inc

Suletud

SektorTervishoid

2.78 0.72

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.76

Max

2.8

Põhinäitajad
By Trading Economics
Sissetulek	22M 9.7M
Müük	586K 718K
Kasumimarginaal	1,345.822
Töötajad	23
EBITDA	-152K -12M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+71.67% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	368M 507M
Eelmine avamishind	2.06
Eelmine sulgemishind	2.78

Uudiste sentiment

By Acuity

21%

79%

65 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.275 / 0.33 Toetus ja vastupanu

Ovid therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. mai 2026, 23:43 UTC

Uudisväärsed sündmused

New Zealand's Unemployment Rate Falls in 1Q

5. mai 2026, 23:20 UTC

Kuumad aktsiad

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5. mai 2026, 21:48 UTC

Tulu

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5. mai 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6. mai 2026, 00:00 UTC

Market Talk

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5. mai 2026, 23:39 UTC

Market Talk

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5. mai 2026, 22:26 UTC

Market Talk

AMD Data-Center Business Continues to Surge -- Market Talk

5. mai 2026, 22:20 UTC

Market Talk

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5. mai 2026, 22:08 UTC

Tulu

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5. mai 2026, 22:07 UTC

Tulu

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. mai 2026, 21:48 UTC

Tulu

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5. mai 2026, 21:48 UTC

Tulu

Pan American Silver 1Q Rev $1.2B >PAAS

5. mai 2026, 21:42 UTC

Tulu

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5. mai 2026, 21:38 UTC

Tulu

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. mai 2026, 21:30 UTC

Tulu

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5. mai 2026, 21:29 UTC

Tulu

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. mai 2026, 21:26 UTC

Tulu

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5. mai 2026, 21:25 UTC

Tulu

Alcon Inc. 1Q EPS 39c >ALC.EB

5. mai 2026, 21:25 UTC

Tulu

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5. mai 2026, 21:24 UTC

Tulu

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. mai 2026, 21:18 UTC

Tulu

Mistras Backs 2026 Rev $730M-$750M >MG

5. mai 2026, 21:17 UTC

Tulu

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5. mai 2026, 21:15 UTC

Tulu

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5. mai 2026, 21:12 UTC

Tulu

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5. mai 2026, 21:11 UTC

Tulu

SSR Mining 1Q Rev $581.8M >SSRM

5. mai 2026, 21:10 UTC

Tulu

SSR Mining 1Q Adj EPS $1.15 >SSRM

5. mai 2026, 21:10 UTC

Tulu

SSR Mining 1Q EPS $1.16 >SSRM

5. mai 2026, 21:08 UTC

Tulu

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5. mai 2026, 21:01 UTC

Tulu

Intact Financial 1Q EPS C$4.12 >IFC.T

5. mai 2026, 21:01 UTC

Kuumad aktsiad

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Võrdlus sarnastega

Hinnamuutus

Ovid therapeutics Inc Prognoos

Hinnasiht

By TipRanks

71.67% tõus

12 kuu keskmine prognoos

Keskmine 5.03 USD 71.67%

Kõrge 7 USD

Madal 4 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Ovid therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Ovid therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.275 / 0.33Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

65 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.